|
(Health-NewsWire.Net, July 17, 2015 ) Hemophilia B - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Hemophilia B - Pipeline Review, H1 2015” which provides an overview of the Hemophilia B Therapeutic pipeline.
This report gives far reaching data on the remedial improvement for Hemophilia B, complete with relative examination at different stages, therapeutics appraisal by medication target, component of activity (MoA), course of organization (RoA) and atom sort, alongside most recent overhauls, and included news and press discharges. It additionally audits key players included in the remedial improvement for Hemophilia B and exceptional components on late-stage and suspended activities.
The report improves choice making capacities and help to make viable counter systems to increase upper hand. It reinforces R&D pipelines by distinguishing new targets and MOAs to deliver first-in-class and best-in-class items.
Complete report on H1, 2015 Pipeline Review of “Hemophilia B” addition with 35 market data tables and 15 figures, spread across 106 pages is http://www.rnrmarketresearch.com/hemophilia-b-pipeline-review-h1-2015-market-report.html .
This report highlights investigational medications from crosswise over globe covering more than 20 treatment regions and about 3,000 signs. The report is fabricated utilizing information and data sourced from Global Markets Direct's exclusive databases, Company/University sites, SEC filings, financial specialist presentations and included press discharges from organization/college destinations and industry-particular outsider sources, set up together by Global Markets Direct's group. Medication profiles/records highlighted in the report experiences occasional updation taking after a stringent arrangement of procedures that guarantees that every one of the profiles are upgraded with the most recent arrangement of data. Moreover, procedures including live news & arrangements following, program based ready box and clinical trials registries following guarantee that the latest improvements are caught on an ongoing premise.
Drugs Profile Discussed in this Research :
albutrepenonacog alfa, ALN-AT3, AMT-060, AZ-10047130, BAX-335, BAY-1093884, CB-2679d, Cell Therapy for Hemophilia B, coagulation factor IX (recombinant), coagulation factor VIIa (recombinant), concizumab, CSL-689, DTX-101, Gene Therapy for Hemophilia B, Gene Therapy to Activate Factor IX for Hemophilia B, LR-769, MOD-5014, nonacog alfa biosimilar, nonacog beta pegol, PF-05280602, Recombinant Enzyme to Replace Factor IX for Hemophilia B, SHP-624, SPK-FIX and SVF-VIIa
Companies Discussed/Mentioned in this Research:
Alnylam Pharmaceuticals, Inc., Amarna Therapeutics B.V., AstraZeneca PLC, Bayer AG, Biogen, Inc.,Catalyst Biosciences, Inc., CSL Limited, Dimension Therapeutics, Inc., Emergent BioSolutions Inc., Novo Nordisk A/S, OPKO Health, Inc., Pharming Group N.V., rEVO Biologics, Sangamo BioSciences, Inc., Spark Therapeutics, Inc., The International Biotechnology Center (IBC) "Generium" and uniQure N.V.
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=394565 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Hemophilia B
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Hemophilia B and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Hemophilia B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Hemophilia B pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Hemophilia B
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Hemophilia B pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Hematology Therapeutics Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
